title: Donor cell leukaemia after allogeneic haematopoietic SCT followed by prolonged thalidomide maintenance for multiple myeloma.
authors.forename: T S Y
authors.initials: TS
authors.lastname: Chan
authors.forename: W-Y
authors.initials: WY
authors.lastname: Au
authors.forename: K
authors.initials: K
authors.lastname: Lam
authors.forename: Y-F
authors.initials: YF
authors.lastname: Lam
authors.forename: C-C
authors.initials: CC
authors.lastname: So
authors.forename: A Y H
authors.initials: AY
authors.lastname: Leung
authors.forename: E
authors.initials: E
authors.lastname: Tse
authors.forename: A K W
authors.initials: AK
authors.lastname: Lie
authors.forename: Y-L
authors.initials: YL
authors.lastname: Kwong
mesh_terms: D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000209:etiology*; D013792:Thalidomide / Q000008:administration & dosage*; D014184:Transplantation, Homologous
chemical_list: D007166:Immunosuppressive Agents; D013792:Thalidomide